71
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Anticlastogenic effect of diosgenin on 7,12-dimethylbenz(a)anthracene treated experimental animals

, , , , &
Pages 77-85 | Received 17 Apr 2012, Accepted 06 Aug 2012, Published online: 03 Oct 2012
 

Abstract

The present investigation explores the anticlastogenic effect of diosgenin on 7,12-dimethylbenz(a)anthracene (DMBA) treated clastogenesis. The frequency of bone marrow micronucleated polychromatic erythrocytes (MnPCEs), chromosomal aberrations (CA), deoxyribonucleic acid (DNA) damage as cytogenetic markers and the levels of lipid peroxidation by-products, activities of enzymatic antioxidant and the status of detoxification agents were performed to assess the anticlastogenic effects of diosgenin on DMBA treated hamsters. Intraperitoneal injection of DMBA (30 mg/kg bw) leads to clastogenesis in hamster. Elevated MnPCEs frequencies, CA, DNA damage, enhanced lipid peroxidation by products, declined antioxidant activities and detoxification cascade were observed in DMBA treated hamsters. Oral pretreatment with diosgenin (80 mg/kg bw) daily for a period of five days significantly reduced the frequency of MnPCEs, CA, DNA damage and normalized the levels of lipid peroxidation by products with increased activities of antioxidants and detoxification agents in DMBA alone treated hamsters. Outcome of the present study revealed that diosgenin has potent anticlastogenic effects on DMBA treated hamsters.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.